Pilocarpine used to treat xerostomia in patients submitted to radioactive iodine therapy: a pilot study

Juliana Pereira Almeida, Luiz Paulo Kowalski, Juliana Pereira Almeida, Luiz Paulo Kowalski

Abstract

Xerostomia complaint is very commonly associated to radioactive iodine therapy. Alternatives to treat this morbidity can offer better quality of life to patients with thyroid cancer submitted to adjuvant iodine therapy.

Aim: to report on the experience with pilocarpine on the treatment of xerostomia in thyroid cancer patients submitted to adjuvant radioactive iodine therapy (RIT).

Materials and methods: The five patients who met the inclusion criteria received 5mg of pilocarpine, 3 tid for one week. Side effects of the drug and subjective response to xerostomia complaints after treatment were evaluated.

Design: it is a prospective, non-randomized study.

Results: Sudoresis was the most frequent side effect of pilocarpine use, followed by fatigue and headache. Two patients reported relief of xerostomia using pilocarpine, but only one patient was able to tolerate the side effects.

Conclusions: Pilocarpine seems to relieve xerostomia complaints in thyroid cancer patients because it is able to stimulate salivary flow, but the observed side effects made the patients refuse long-term therapy continuation.

References

    1. Newkirk KA, Ringel MD, Wartofsky L, Burman KD. The role of radioactive iodine in salivary gland dysfunction. Ear Nose Throat J. 2000;79(6):460–468.
    1. Alexander C, Bader JB, Schaefer A, Finke C, Kirsch CM. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med. 1998;39(9):1551–1554.
    1. Bushnell DL, Boles MA, Kaufman GE, Wadas MA, Barnes E. Complications, sequela and dosimetry of iodine-131 therapy for thyroid carcinoma. J Nucl Med. 1992;33(12):2214–2221.
    1. Jensen SB, Pedersen AM, Reibel J, Nauntofte B. Xerostomia and hypofunction of the salivary glands in cancer therapy. Support Care Cancer. 2003;11(4):207–225.
    1. Caglar M, Tuncel M, Alpar R. Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment. Clin Nucl Med. 2002;27(11):767–771.
    1. Koseki M, Maki Y, Matsukubo T, Ohashi Y, Tsubota K. Salivary flow and its relationship to oral signs and symptoms in patients with dry eyes. Oral Dis. 2004;10(2):75–80.
    1. Fox PC. Salivary enhancement therapies. Caries Res. 2004;38(3):241–246.
    1. LeVeque FG, Montgomery M, Potter D, Zimmer MB, Rieke JW, Steiger BW, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J Clin Oncol. 1993;11(6):1124–1131.
    1. Hamlar DD, Schuller DE, Gahbauer RA, Buerki RA, Staubus AE, Hall J, et al. Determination of the efficacy of topical oral pilocarpine for postradiation xerostomia in patients with head and neck carcinoma. Laryngoscope. 1996;106(8):972–976.
    1. Zimmerman RP, Mark RJ, Tran LM, Juillard GF. Concomitant pilocarpine during head and neck irradiation is associated with decreased posttreatment xerostomia. Int J Radiat Oncol Biol Phys. 1997;37(3):571–575.
    1. Horiot JC, Lipinski F, Schraub S, Maulard-Durdux C, Bensadoun RJ, Ardiet M, et al. Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study. Radiother Oncol. 2000;55(3):233–239.
    1. Leek H, Albertsson M. Pilocarpine treatment of xerostomia in head and neck patients. Micron. 2002;33(2):153–155.
    1. Haddad P, Karimi M. A randomized, double-blind, placebo-controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation-induced xerostomia. Radiother Oncol. 2002;64(1):29–32.
    1. Gorsky M, Epstein JB, Parry J, Epstein MS, Le ND, Silverman S., Jr The efficacy of pilocarpine in cancer patients with hyposalivation following radiation therapy. Oral Surg Oral Med Oral Pathol. 2004;97(2):190–195.
    1. Mosqueda-Taylor A, Luna-Ortiz K, Irigoyen-Camacho ME, Díaz-Franco MA, Coll-Muñoz AM. Efecto del clorhidrato de pilocarpina como estimulante de la producción salival en pacientes sometidos a radioterapia de cabeza y cuello. Med Oral. 2004;9(3):204–211.
    1. Silberstein EB. Reducing the incidence of 131I-induced sialadenitis: the role of pilocarpine. J Nucl Med. 2008;49(4):546–549.
    1. Aframian DJ, Helcer M, Livni D, Markitziu A. Pilocarpine for the treatment of salivary glands' impairment caused by radioiodine therapy for thyroid cancer. Oral Dis. 2006;12(3):297–300.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren